Introduction
============

Voriconazole, a broad-spectrum antifungal agent, is a second-generation triazole with a structure similar to that of fluconazole, but with improved potency \[[@B1][@B2]\]. It exhibits the antifungal effect primarily by inhibiting the action of fungal cytochrome P450, reducing the synthesis of ergosterol, and inhibiting the synthesis of fungal cell membrane \[[@B3][@B4]\].

Voriconazole is effective in the treatment of severe, invasive fungal infections including invasive aspergillosis and candidemia \[[@B5][@B6]\]. It is currently marketed as 50 mg and 200 mg film-coated tablets, a 40 mg/ml powder for oral suspension, and a 200 mg powder for infusion (Vfend^®^, Pfizer, New York City, NY, USA).

Synthon BV (Nijmegen, Netherlands) has developed voriconazole 200 mg powder for infusion; compared with Vfend^®^ 200 mg powder for infusion (Pfizer, USA), in this formulation, lactose is used as an additional excipient and sulfobutyl ether cyclodextrin is replaced with hydroxypropyl beta-cyclodextrin \[[@B7]\]. Vorico^®^ Injection 200 mg (Chong Kun Dang Pharm., Seoul, Korea) contains the same ingredients as voriconazole 200 mg powder for infusion (Synthon BV, Nijmegen, Netherlands).

The primary objective of this randomized, open-label, single-dose, three-group, two-treatment, two-sequence, two-period, crossover, phase I clinical study was to assess the pharmacokinetic equivalence of Vorico^®^ Injection 200 mg (test formulation) to Vfend^®^ IV 200 mg (reference formulation). The secondary objectives were to compare the pharmacokinetic profile and safety of the test and reference formulations.

Materials and Methods
=====================

1. Subjects {#sec1}
-----------

The subjects eligible for this study were healthy male volunteers aged between 19 and 55 years with body weight of ≥50 kg and a body mass index (BMI) of 18.5 -- 30.0 kg/m^2^. To eliminate the potential variability in pharmacokinetic characteristics arising due to sex, only male subjects were eligible in the study. The subjects exhibited no clinically significant abnormalities, as revealed by their medical history, vital signs, physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG). The exclusion criteria were as follows: positive for hepatitis B surface antigen or hepatitis C or HIV antibodies at screening; 12-lead ECG with QTc \>440 ms, PR \<110 ms, PR \>200 ms, QRS \<60 ms, or QRS \>110 ms at screening; and exposure to St John\'s Wort, rifabutin, rifampicin, carbamazepine, phenobarbital, high-dose ritonavir, terfenadine, astemizole, cisapride, pimozide, quinidine, sirolimus, ergot alkaloids (ergotamine and dihydroergotamine), or efavirenz within 1 month before the first administration of the investigational product.

2. Study design {#sec2}
---------------

This was a randomized, open-label, single-dose, three-group, two-treatment, two-sequence, two-period, crossover phase I trial (ClinicalTrials.gov identifier: [NCT02631954](http://clinicaltrials.gov/ct2/show/NCT02631954)). The study was approved by the Institutional Review Board of Inha University Hospital (IRB protocol \#15-057; Incheon, Korea) and the Korean Ministry of Food and Drug Safety (MFDS). The study was conducted in accordance with the Declaration of Helsinki and Guideline for Good Clinical Practice. All subjects signed informed consent form before study enrollment.

Screening was conducted 28 to 2 days before the first dosing. For each group, eight eligible subjects were hospitalized in the inpatient clinical trial unit and were randomly assigned to one of the two sequences on the day before the first dosing and received a single dose of 200 mg test or reference formulation intravenously on day 1. The investigational products were administered at approximately 8 to 9 a.m. after an overnight fast for at least 10 h. The prepared investigational products were administered intravenously at a constant rate of 33.3 mL/h over a 1.5-h period using an infusion pump. At the end of the infusion, approximately 12 -- 15 mL of saline was flushed within 1 min to ensure that no investigational product remained in the intravenous administration line. The subjects were maintained under a fasting state until 4 h after the initiation of drug administration, except for water consumption 2 h after the initiation of dosing. The subjects were discharged on day 2. The washout period was 7 days; the second period was scheduled similar to the first period, except for the administration of the investigational product. An end-of-study (EOS) visit took place on days 13 -- 20. Throughout the study period, alcohol consumption, heavy exercise, and concomitant drug (s) use were not allowed.

3. Investigational product preparation {#sec3}
--------------------------------------

To prepare 20 mL of translucent and 10 mg/mL of concentrated voriconazole solutions, 19 mL of sterile water was added to the test or reference formulation powder using an 18- or 20-G needle. Twenty milliliters of the concentrated voriconazole solution was drawn using a 50-mL syringe. Sterile saline solution (0.9% NaCl) was further drawn into the syringe to a final volume of 50 mL. The prepared solution contained 4 mg/mL voriconazole. The syringe was inverted 3 -- 4 times to thoroughly mix the solution.

4. Assessments {#sec4}
--------------

Blood samples were collected prior to the start of infusion (SOI) (*i.e.*, pre-dose), and at 0.5, 1, 1.25, 1.5 (before the end of infusion \[EOI\]), 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, and 24 h after the SOI for both the test and reference formulations. Plasma voriconazole concentration was detected using a validated LC-MS/MS method.

Adverse events (AEs) and the use of concomitant medication were monitored over the course of the study. Vital signs were evaluated at screening; on day -1, 1, and 2 in each period; and at the EOS visit. Clinical laboratory analyses were conducted at screening, on day -1 for each period, and at the EOS visit. A 12-lead ECG was conducted at screening and the EOS visit. A physical examination was performed at screening, on days 1 and 2 in each period, and at the EOS visit.

5. Endpoints {#sec5}
------------

Primary pharmacokinetic endpoints were the area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC~last~) and maximum plasma concentration (C~max~) of voriconazole. Secondary pharmacokinetic endpoints were the time to C~max~ (T~max~); AUC from time to zero to infinity (AUC~inf~); ratio of AUC~last~ to AUC~inf~ (AUC~last/inf~); terminal elimination rate constant (λ~z~); and terminal half-life (t~½~). Safety endpoints (*e.g.*, AEs) were also evaluated, as described above.

6. Statistical analysis {#sec6}
-----------------------

The sample size was calculated from a coefficient of variation of 12.3% \[[@B7]\] and geometric mean (GM) ratios for the primary pharmacokinetic endpoints of 1.05. A sample size of 10 was required to afford sufficient statistical power (80%) for the 90% confidence interval (CI) of the GM ratios of AUC~last~ and C~max~ to satisfy the pre-specified criteria for equivalence margin of 0.8 -- 1.25. The sample size was determined based on two one-sided tests procedure with 0.05 level of significance for the GM ratio. Considering the dropout, the study sample size was calculated to be 24 (8 subjects per group).

All statistical analyses and pharmacokinetic analysis were conducted using SPSS^®^ version 19.0 (IBM Corp. Armonk, NY, USA) and Phoenix WinNonlin^®^ version 6.4 (Certara USA, Inc., Princeton, NJ, USA). Pharmacokinetic analysis was performed in the pharmacokinetic population, which included all subjects who had received a complete dose of the study drug and provided at least one post-dose blood sample with a voriconazole concentration. Pharmacokinetic parameters were calculated using non-compartmental methods. The AUC~last~ was calculated using the linear up/log down trapezoidal method, and the C~max~ was obtained directly from the concentration--time data. The AUC~inf~ was calculated as AUC~last~ + C~last~/λ~z~, where C~last~ was the last observable concentration and λ~z~ was estimated at the terminal phase by linear regression after log-transformation of the concentrations. The ANOVA was performed on the natural logarithm transformed AUC~last~ and C~max~ values, and *P* \<0.05 indicted significance. The ANOVA model considered group effect, sequence nested within group effect, period nested within group effect, treatment effect, and interaction between treatment and group effect as fixed factors. Subject within sequence-by-group interaction effect was considered a random factor. Bioequivalence was attained if 90% CIs for the GM ratios of AUC~last~ and C~max~ were within the 0.8 -- 1.25 predefined equivalence boundary for the comparisons of test and reference formulation.

The safety data were analyzed in the safety population, which comprised all subjects who had been randomly assigned to a sequence and who had received either a complete or partial dose of the study drug. AEs were listed according to the organ system class and preferred terms (Medical Dictionary for Regulatory Activities \[MedDRA\], version 17.0) and were summarized by relationship to treatment. All safety data were evaluated descriptively.

Results
=======

1. Subjects {#sec1___1}
-----------

Twenty-five healthy Korean male subjects were enrolled and randomized, and one randomized subject dropped out before the administration of the study drug. The remaining 24 subjects received the study drug, and they were included in the safety population. Age, height, weight, and BMI of the safety population were 28.0 ± 6.7 (mean ± standard deviation) years, 173.3 ± 6.1 cm, 70.0 ± 9.7 kg, and 23.3 ± 2.7 kg/m^2^, respectively. Among the 24 subjects who received the study drug, one subject withdrew consent before the second period. Twenty-three subjects completed the study without major deviation, and they were included in the pharmacokinetic population.

2. Pharmacokinetics {#sec2___1}
-------------------

Pharmacokinetic parameters were determined based on the plasma voriconazole concentration data obtained from the pharmacokinetic population. Following intravenous administration of a single 200 mg dose, both test and reference formulations showed similar mean voriconazole plasma concentration--time profiles ([Fig. 1](#F1){ref-type="fig"}). The pharmacokinetic parameters for voriconazole are summarized in [Table 1](#T1){ref-type="table"}. The mean (standard deviation \[SD\]) AUC~last~ value was 7,469.78 (3,125.73) h·ng/mL for the test formulation and 6,966.17 (2,856.10) h·ng/mL for the reference formulation. The mean (SD) C~max~ value was 1,997.0 (406.2) ng/mL for the test formulation and 2,433.7 (2,456.9) ng/mL for the reference formulation. For each primary endpoint (AUC~last~ and C~max~), the 90% CIs of the GM ratios for the test formulation to reference formulation were all within the pre-specified margin for bioequivalence of 0.8 -- 1.25 ([Table 2](#T2){ref-type="table"}). The secondary pharmacokinetic endpoints including T~max~, AUC~inf,~ AUC~last/inf~, λ~z~, and t~½~ were comparable between the two treatments.

![Mean (± standard deviation) plasma voriconazole concentration against time, following a single intravenous dose of the reference or test formulation for 1.5 h in healthy male subjects (pharmacokinetic population): (A) linear scale, (B) semi-logarithmic scale.\
^a^Vorico^®^ Injection 200 mg.\
^b^Vfend^®^ IV 200 mg.](ic-52-204-g001){#F1}

###### Summary of the pharmacokinetic parameters (pharmacokinetic population)

![](ic-52-204-i001)

  Pharmacokinetic Parameters   Test^a^ (n = 23)   Reference^b^ (n = 23)              
  ---------------------------- ------------------ ---------------------------------- ----------------------------------
  T~max~ (h)                                                                         
                               Mean (SD)          1.58 (0.04)                        1.57 (0.03)
                               Median (range)     1.58 (1.50 -- 1.67)                1.58 (1.50 -- 1.60)
  C~max~ (ng/mL)                                                                     
                               Mean (SD)          1,997.0 (406.2)                    2,433.7 (2,456.9)
                               Median (range)     2,048.4 (1,408.2 -- 3,015.6)       1,878.5 (1,323.0 -- 13,571.2)
  AUC~last~ (h·ng/mL)                                                                
                               Mean (SD)          7,469.78 (3,125.73)                6,966.17 (2,856.10)
                               Median (range)     6,435.36 (3,609.09 -- 16,068.04)   6,166.75 (3,626.56 -- 13,344.14)
  AUC~inf~ (h·ng/mL)                                                                 
                               Mean (SD)          8,631.50 (4,401.54)                8,159.24 (4,905.05)
                               Median (range)     7,854.27 (3,802.38 -- 19,588.18)   6,458.54 (3,747.04 -- 25,352.31)
  AUC~last/inf~                                                                      
                               Mean (SD)          0.90 (0.09)                        0.91 (0.10)
                               Median (range)     0.93 (0.68 -- 0.98)                0.94 (0.53 -- 0.98)
  λ~z~ (1/h)                                                                         
                               Mean (SD)          0.10 (0.04)                        0.10 (0.03)
                               Median (range)     0.10 (0.05 -- 0.22)                0.10 (0.03 -- 0.13)
  t~½~ (h)                                                                           
                               Mean (SD)          7.98 (2.92)                        8.42 (4.61)
                               Median (range)     6.91 (3.15 -- 15.22)               6.92 (5.38 -- 26.82)

^a^Vorico^®^ Injection 200 mg.

^b^Vfend^®^ IV 200 mg.

T~max,~ time to C~max~; SD, standard deviation; C~max,~ maximum plasma concentration; AUC~last,~ area under the concentration--time curve from time zero to the last quantifiable concentration; AUC~inf,~ area under the concentration--time curve from time zero to infinity; AUC~last/inf,~ ratio of AUC~last~ to AUC~inf~; λ~z,~ terminal elimination rate constant; t~½,~ terminal half-life.

###### Statistical analysis of the primary pharmacokinetic endpoints (pharmacokinetic population)

![](ic-52-204-i002)

  Endpoints             Geometric mean   Geometric mean ratio (90% CI)   
  --------------------- ---------------- ------------------------------- ---------------------------
  AUC~last~ (h·ng/mL)   6,964.44         6,496.96                        1.0720 (1.0262 -- 1.1198)
  C~max~ (ng/mL)        1,956.22         2,044.10                        0.9570 (0.8178 -- 1.1199)

^a^Vorico^®^ Injection 200 mg.

^b^Vfend^®^ IV 200 mg.

CI, confidence interval; AUC~last,~ area under the concentration--time curve from time zero to the last quantifiable concentration; C~max,~ maximum plasma concentration.

3. Safety {#sec3___1}
---------

During the study, there were no treatment-emergent AEs (TEAEs) which resulted in study discontinuation and there were no serious AEs. All TEAEs had relationship to the study drug.

Fifty-eight TEAEs were mild, and 28 cases were related to the reference formulation, where 30 cases were related to the test formulation ([Table 3](#T3){ref-type="table"}). All 24 (100%) subjects experienced one or more TEAEs. All subjects recovered from the TEAEs without any sequelae. Photophobia (39 cases), dizziness (6 cases), headache (2 cases), vision blurred (2 cases), and visual impairment (2 cases) were the common TEAEs. TEAEs were reported in 21 (91.3%) out of the 23 subjects who received the reference formulation and in 22 (91.7%) of the 24 subjects who received the test formulation; there was no statistically significant difference between the two formulations (*P*-value = 1.0; Fisher\'s exact test).

###### Treatment-emergent adverse events according to the preferred term (safety population)

![](ic-52-204-i003)

  TEAEs                                             Test^a^ (n = 24)                   Reference^b^ (n = 23)   
  ------------------------------------------------- ---------------------------------- ----------------------- ----
  Eye disorders                                                                                                
                                                    Colour blindness acquired                                  1
                                                    Photophobia                        21                      18
                                                    Vision blurred                                             2
                                                    Visual impairment                  1                       1
  Investigations                                                                                               
                                                    Blood glucose increased            1                       
                                                    Lymphocyte count decreased         1                       
                                                    Urine oxalate increased            1                       
                                                    White blood cells urine positive                           1
  Nervous system disorders                                                                                     
                                                    Headache                           2                       
  Respiratory, thoracic and mediastinal disorders                                                              
                                                    Nasal congestion                                           1
  Vascular disorders                                                                                           
                                                    Dizziness                          3                       3
                                                    Epistaxis                                                  1
  Total                                             30                                 28                      

^a^Vorico^®^ Injection 200 mg.

^b^Vfend^®^ IV 200 mg.

TEAE, treatment-emergent adverse event.

No treatment-related trends were founded in the results of clinical laboratory tests, vital signs, ECG, or physical examination.

Discussion
==========

In the present study, the pharmacokinetic equivalence of a test formulation (Vorico^®^ Injection) and a reference formulation (Vfend^®^ IV) of voriconazole and their safety were evaluated. It has been reported that the genetic polymorphism in *CYP2C19* is a major contributing factor for the highly variable pharmacokinetics of voriconazole \[[@B8][@B9][@B10][@B11]\]. The pharmacokinetic endpoints determined in this study were comparable to those determined in clinical studies conducted in healthy male Koreans to assess the effect of *CYP2C19* polymorphism on the pharmacokinetics of voriconazole \[[@B12][@B13]\]. After a single intravenous administration of 200 mg voriconazole in healthy Koreans, the mean (SD) t~½~ of extensive metabolizers, heterozygous extensive metabolizers, and poor metabolizers according to the *CYP2C19* genotype group were found to be 3.2 (2.5) h, 5.5 (3.3) h, and 13.3 (6.1) h, respectively \[[@B13]\]. The mean (SD) and median (range) of the t½ obtained in our present study were 7.98 (2.92) h and 6.91 (3.15-15.22) h, respectively, for the test formulation and 8.42 (4.61) h and 6.92 (5.38-26.82) h, respectively, for the reference formulation.

The safety profiles of the test and reference formulations were comparable. No serious AEs occurred; overall, there were no unexpected safety results over the course of the study. Similar to the results of previous studies on voriconazole \[[@B13][@B14][@B15][@B16]\], a transient visual disturbance occurred shortly after dosing and it lasted a few minutes. The characteristics of eye disorders reported in this study were similar to the results of a double-blind, placebo-controlled study on the effects of multiple voriconazole doses on the vision of healthy volunteers. They which exhibited nonprogressive and reversible effects on altered visual perception, electroretinograms, color vision, and static visual field thresholds over the treatment period \[[@B17]\].

In this study, 24 subjects were divided into three groups in consideration of effective drug administration and safety monitoring. This group effect was considered in the ANOVA model. However, the findings of the current study have a limitation regarding the open-label design and the inclusion of only healthy male volunteers. Because the primary aim of this study was to assess the pharmacokinetic equivalence of two formulations of voriconazole, an open-label design was adopted. However, the results of the current study cannot be generalized to female or older (\>55 years) patient populations owing to the limitation with regard to the study design; the study also included only male volunteers aged between 19 and 55 years.

In conclusion, this phase I trial demonstrated equivalent pharmacokinetic characteristics between Vorico^®^ Injection 200 mg and Vfend^®^ IV 200 mg, which satisfied the criteria of bioequivalence with respect to the primary endpoints, the AUC~last~ and C~max~ of voriconazole, after a single intravenous dose crossover administration under fasting conditions. Additionally, both formulations exhibited similar safety and tolerability.
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